NFE2L2 and fatty liver disease: The list of AOPs used for the completion of the full steatosis pathway is: 34 (LXR activation leading to hepatic steatosis), 36 (Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis), 57 (AhR activation leading to hepatic steatosis), 58 (NR1I3 (CAR) suppression leading to hepatic steatosis), 60 (NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis), 61 (NFE2L2/FXR activation leading to hepatic steatosis).